This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 "Mental Health Research Grants" provides $560,641 to Psychogenics Inc. to develop an innovative drug repurposing platform for rare diseases and psychiatric disorders. The goal is to create an electroencephalogram (EEG)-based screening platform, called eCube, that can compare EEG signatures of reference drugs against disease animal models to generate hypotheses for potential drug repurposing. This "Drug EEG Signature Analysis" approach aims to improve the success rate of central nervous system drug discovery, particularly for rare diseases, by leveraging existing compounds in a target-agnostic manner. If successful, the platform will be offered as a fee-for-service or used in collaborative drug development efforts by Psychogenics and its partners.
Generated 3/4/25, 5:56 AM